Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

被引：0
|
作者：
Anne Julienne Genuino
Usa Chaikledkaew
Anna Melissa Guerrero
Thanyanan Reungwetwattana
Ammarin Thakkinstian
机构：
[1] Mahidol University Health Technology Assessment (MUHTA) Graduate Program,Pharmaceutical Division
[2] Department of Health Philippines,Social and Administrative Pharmacy Excellence Research (SAPER) Unit
[3] Department of Pharmacy,Division of Medical Oncology
[4] Faculty of Pharmacy,Section for Clinical Epidemiology and Biostatistics
[5] Mahidol University,undefined
[6] Department of Medicine,undefined
[7] Faculty of Medicine Ramathibodi Hospital,undefined
[8] Mahidol University,undefined
[9] Faculty of Medicine Ramathibodi Hospital,undefined
来源：
BMC Health Services Research | / 19卷
关键词：
Adjuvant trastuzumab; Cost-utility analysis; HER2-positive; Breast cancer; Cost-effectiveness; Philippines;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Genuino, Anne Julienne
    Chaikledkaew, Usa
    Guerrero, Anna Melissa
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    [J]. BMC HEALTH SERVICES RESEARCH, 2019, 19 (01)
  • [2] Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis
    Leung, William
    Kvizhinadze, Giorgi
    Nair, Nisha
    Blakely, Tony
    [J]. PLOS MEDICINE, 2016, 13 (08):
  • [3] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Schwartz, Naomi R. M.
    Flanagan, Meghan R.
    Babigumira, Joseph B.
    Steuten, Lotte M.
    Roth, Joshua A.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10): : 1133 - 1139
  • [4] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Tran, Phuong T.
    Diaby, Vakaramoko
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 221 - 221
  • [5] Cost-effectiveness analysis (CEA) of adjuvant trastuzumab therapy use in HER2-positive early-stage breast cancer (EBC)
    Quintyne, K. I.
    Woulfe, B.
    Dee, A.
    Gupta, R.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] COST-UTILITY ANALYSIS OF TRASTUZUMAB IN TREATMENT OF METASTATIC HER2-POSITIVE BREAST CANCER IN VIETNAM
    Nguyen, T. T. C.
    Nguyen, T. T. T.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A643 - A643
  • [7] COST-EFFECTIVENESS ANA LYSIS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY OF EARLY-STAGE HER2-POSITIVE BREAST CANCER
    Nguyen, T. T. C.
    Nguyen, T. T. T.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A735 - A735
  • [8] Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
    Hajjar, Ali
    Ergun, Mehmet A.
    Alagoz, Oguzhan
    Rampurwala, Murtuza
    [J]. PLOS ONE, 2019, 14 (06):
  • [9] Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
    Goldvaser, Hadar
    Korzets, Yasmin
    Shepshelovich, Daniel
    Yerushalmi, Rinat
    Sarfaty, Michal
    Ribnikar, Domen
    Thavendiranathan, Paaladinesh
    Amir, Eitan
    [J]. JNCI CANCER SPECTRUM, 2019, 3 (02)
  • [10] Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
    Genuino, Anne Julienne
    Chaikledkaew, Usa
    The, Due Ong
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (08) : 815 - 824
12345